Methylenedioxymethamphetamine induces opposite changes in central pre- and postsynaptic 5-HT1A receptors in rats.
Norberto Aguirre, J L Galbete, Berta Lasheras, J Del Río
European Journal of Pharmacology July 1, 1995 DOI: 10.1016/0014-2999(95)00303-3 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal experimental study Peer reviewed |
|---|---|
| Population | Rat brain tissue (frontal cortex and brain stem region containing the dorsal raphe nucleus) |
| Interventions | 3 'ecstasy') |
| Measures | [3H]8-Hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT) binding, [3H]paroxetine binding, serotonin (5-hydroxytryptamine, 5-HT) content |
| Topics | Serotonin MDMA |
| Keywords | Raphe nuclei Frontal lobe Dendrites Synapses Animals Rats, wistar N-methyl-3,4-methylenedioxyamphetamine Hydroxyindoleacetic acid Receptors, serotonin Serotonin agents Time factors Male |
| Key findings | Repeated MDMA administration reduced 5-HT1A receptor density in the brain stem (dorsal raphe region), while both single and repeated MDMA increased or tended to increase 5-HT1A receptor number in the frontal cortex, with the effect more marked after repeated dosing. Both schedules reduced frontal cortex serotonin content and [3H]paroxetine binding but not in the brain stem. |
Abstract
The present study examined the short- and long-term effects of single and repeated administration of 3,4-methylenedioxy-methamphetamine (MDMA, 'ecstasy') on somatodendritic and postsynaptic 5-HT1A receptors of the rat brain. [3H]8-Hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT) was used to label 5-HT1A receptors in the brain stem region containing the dorsal raphe nucleus and in the frontal cortex. As expected, both schedules of treatment reduced the serotonin (5-hydroxytryptamine, 5-HT) content and [3H]paroxetine binding in the frontal cortex but not in the brain stem. Multiple but not single MDMA administration significantly reduced 5-HT1A receptor density in the selected brain stem region. In the frontal cortex, both MDMA treatments increased or tended to increase 5-HT1A receptor number, the effect being more marked after repeated drug administration.
Comparable studies
Other preclinical and animal studies on MDMA, most cited first.
Citations in the library
Cited by 13
- Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy Journal of Psychopharmacology 2005
- Methylenedioxymethamphetamine (MDMA): Serotonergic and dopaminergic mechanisms related to its use and misuse Journal of Neurochemistry March 12, 2021
- Studies on the mechanisms underlying amiloride enhancement of 3,4-methylenedioxymethamphetamine-induced serotonin depletion in rats. European Journal of Pharmacology May 21, 2007
- Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): Neurodegeneration versus Neuromodulation Pharmaceuticals July 5, 2011
- The role of 5-HT1A and 5-HT1B receptors in MDMA self-administration 2016
and 8 more in the library
Cites 4
- Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity Journal of Neuroscience August 1, 1988
- Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Journal of Pharmacology and Experimental Therapeutics 1987
- 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Journal of Pharmacology and Experimental Therapeutics September 1, 1987
- The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. European Journal of Pharmacology August 22, 1986